Lupin Limited has informed the Exchange regarding a press release dated January 31, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabineand Tenofovir Alafenamide (DETAF) Tablets.".
Lupin Limited has informed the Exchange regarding a press release dated January 31, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabineand Tenofovir Alafenamide (DETAF) Tablets.".